SCHEMBL4799464

SCHEMBL4799464

Cc1nccc(Oc2ccc(N)cc2C)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 3/20 0.44
FEN1 P39748 3/20 0.44
MAP4K4 O95819 3/20 0.39
ALDH1A1 P00352 2/20 0.37
KEAP1 Q14145 1/20 0.37
SCN5A Q14524 1/20 0.36
SCN9A Q15858 1/20 0.36
PDE10A Q9Y233 1/20 0.34
KDM4E B2RXH2 3/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
ALOX15 P16050 1/20 0.34
GAA P10253 1/20 0.33
MET P08581 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
POLB P06746 1/20 0.33
CASP1 P29466 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4799326 0.85 MAPT (0.46) ALOX5APFEN1ALDH1A1KDM4EKMT2A
SCHEMBL4796075 0.85 ALOX5AP (0.42) ALOX5APFEN1MAP4K4KEAP1SCN5A
SCHEMBL4799451 0.81 ALOX5AP (0.39) ALOX5APFEN1MAP4K4SCN5ASCN9A
SCHEMBL29972178 0.78 KEAP1 (0.40) MAP4K4ALDH1A1KEAP1PDE10AKDM4E
SCHEMBL1643575 0.77 MEN1 (0.47) ALOX5APFEN1MAP4K4ALDH1A1SCN5A
SCHEMBL4795217 0.76 MAP4K4 (0.43) MAP4K4ALDH1A1KEAP1PDE10AKDM4E
SCHEMBL4796549 0.76 KDM4E (0.47) MAP4K4ALDH1A1KEAP1KDM4EKMT2A
SCHEMBL12593846 0.76 KEAP1 (0.62) ALOX5APFEN1MAP4K4ALDH1A1KEAP1
SCHEMBL4329985 0.75 ALDH1A1 (0.56) ALDH1A1PDE10AKDM4EKMT2AMEN1
SCHEMBL30473086 0.75 ALDH1A1 (0.56) ALDH1A1PDE10AKDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC 2005-07-21 US claimed
US-6890924-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2005-05-10 US claimed
EP-1292591-B1 SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2005-02-02 EP claimed
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER PRODUCTS INC. 2002-11-14 US claimed
US-7332493-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth OSI PHARMACEUTICALS (US) 2008-02-19 US disclosed
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC 2005-07-21 US disclosed
US-6890924-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2005-05-10 US disclosed
EP-1292591-B1 SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2005-02-02 EP disclosed
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER PRODUCTS INC. 2002-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 ALOX5AP 3562/4885FEN1 2136/4885MAP4K4 2125/4885
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 ALOX5AP 3963/4885FEN1 2198/4885MAP4K4 2447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.